Back to drug

The Drug-Induced Respiratory Disease Website

Hypersensitivity and infusion reactions. May mimic systemic vasculitis (PMID 30746133). See also under 'Anaphylaxis' (Xf). Hypersensitivity reactions include the rapid development of malaise, cough, dyspnea, wheezing-bronchospasm, cutaneous rash, itching and pruritus. These symptoms may annunciate the onset of anaphylaxis (see Xf) especially if the drug is continued or the patient is inadvertenly rechallenged with the drug. Desensitization can be offered (PMID 26895621), so that patients can receive full treatment courses and need not be switched to an alternative, potentially more toxic or inferior therapy. See PMID 12634903, 12721396, 22149339, 22987983. Skin manifestations at PMID 24820798

Publications

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Jun 01;28;2698-704 — 2010 Jun 01 — 2698-704